GSK has issued a new safety warning on Benlysta with a low frequency risk of serious depression & suicidal ideation; new data added to PI based on new 4003 SLE pt trial with Suicidal ideation seen in 0.7% on BEL and 0.2% on PBO; depression (0.3% vs <0.1%) https://t.co/cMp52MLKxs